We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
Read MoreHide Full Article
Nektar Therapeutics (NKTR - Free Report) announced that it has formed a new wholly-owned subsidiary, Inheris Biopharma, Inc., which will its pipeline of pre-clinical central nervous system (“CNS”) candidates. The new subsidiary will mainly be responsible for the potential launch and commercialization of Nektar’s opioid-based pain candidate, NKTR-181, which is under review in the United States. A decision from the FDA for NKTR-181 is expected by the end of August 2019.
Inheris Biopharma will be led by Jay Galeota, who has been appointed as the president and chief executive officer of the entity. Galeota has more than three decades of experience in the pharma industry. He held several leadership positions at Merck (MRK - Free Report) in the past. Joe Stauffer and George Shiebler have been appointed as chief medical officer, and senior vice president and general counsel, respectively. Both of them have rich experience in their field of work.
The separation will likely help Nektar to collaborate with one or more potential capital partners to commercialize NKTR-181 without impacting the company’s other pipeline candidates.
Shares of the company have increased 0.6% so far this year compared with the industry’s rise of 5.6%.
A potential approval to NKTR-181, which is under review as analgesic for treating chronic low back pain in patients new to any opioid therapy, will be a positive for Nektar. The drug may generate significant sales as low back pain is a major factor leading to disability in adults in the United States. Moreover, NKTR-181, a mu-opioid, has exhibited reduced incidence of euphoria associated with opioids, which can lead to abuse and addiction. This may boost demand for the drug in a country, which is fighting opioid-abuse.
However, investors should be aware of the fact that NKTR-181 may face regulatory and commercialization hurdles due to its opioid-based formulation.
We expect Nektar to focus on its oncology and auto-immune disorder pipeline following the separation of launch activities for NKTR-181 and pre-clinical CNS pipeline into a new subsidiary.
Nektar is developing several immuno-oncology candidates with bempegaldesleukin being its primary candidate. The company is also developing several other candidates across important therapeutic areas including Onzeald in breast cancer and NKTR-255 in virology indications.
The company has collaborations with major pharma companies for developing some of its pipeline candidate. These include Bristol-Myers for bempegaldesleukin, Eli Lilly (LLY - Free Report) for auto-immune disorder candidate, NKTR-358, and Gilead Sciences (GILD - Free Report) for pre-clinical immuno-oncology candidate, NKTR-255.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
Nektar Therapeutics (NKTR - Free Report) announced that it has formed a new wholly-owned subsidiary, Inheris Biopharma, Inc., which will its pipeline of pre-clinical central nervous system (“CNS”) candidates. The new subsidiary will mainly be responsible for the potential launch and commercialization of Nektar’s opioid-based pain candidate, NKTR-181, which is under review in the United States. A decision from the FDA for NKTR-181 is expected by the end of August 2019.
Inheris Biopharma will be led by Jay Galeota, who has been appointed as the president and chief executive officer of the entity. Galeota has more than three decades of experience in the pharma industry. He held several leadership positions at Merck (MRK - Free Report) in the past. Joe Stauffer and George Shiebler have been appointed as chief medical officer, and senior vice president and general counsel, respectively. Both of them have rich experience in their field of work.
The separation will likely help Nektar to collaborate with one or more potential capital partners to commercialize NKTR-181 without impacting the company’s other pipeline candidates.
Shares of the company have increased 0.6% so far this year compared with the industry’s rise of 5.6%.
A potential approval to NKTR-181, which is under review as analgesic for treating chronic low back pain in patients new to any opioid therapy, will be a positive for Nektar. The drug may generate significant sales as low back pain is a major factor leading to disability in adults in the United States. Moreover, NKTR-181, a mu-opioid, has exhibited reduced incidence of euphoria associated with opioids, which can lead to abuse and addiction. This may boost demand for the drug in a country, which is fighting opioid-abuse.
However, investors should be aware of the fact that NKTR-181 may face regulatory and commercialization hurdles due to its opioid-based formulation.
We expect Nektar to focus on its oncology and auto-immune disorder pipeline following the separation of launch activities for NKTR-181 and pre-clinical CNS pipeline into a new subsidiary.
Nektar is developing several immuno-oncology candidates with bempegaldesleukin being its primary candidate. The company is also developing several other candidates across important therapeutic areas including Onzeald in breast cancer and NKTR-255 in virology indications.
The company has collaborations with major pharma companies for developing some of its pipeline candidate. These include Bristol-Myers for bempegaldesleukin, Eli Lilly (LLY - Free Report) for auto-immune disorder candidate, NKTR-358, and Gilead Sciences (GILD - Free Report) for pre-clinical immuno-oncology candidate, NKTR-255.
Nektar Therapeutics Price
Nektar Therapeutics price | Nektar Therapeutics Quote
Zacks Rank
Nektar currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>